- Sevasemten for Becker muscular dystrophy (BMD) in the ongoing GRAND CANYON study;
- EDG-7500 for hypertrophic cardiomyopathy (HCM) in the Phase 2 CIRRUS-HCM trial;
- EDG-15400 for heart failure, where first-in-human dosing began during the quarter.
G&A expenses increased by $0.3 million on a sequential basis as the company added staff and expanded infrastructure to support its pipeline. No revenue was recorded, consistent with the firm’s development-stage status. Despite the wider quarterly loss, Edgewise ended September with $563.3 million in cash, cash equivalents, and marketable securities. The balance, according to the company, is expected to fund ongoing trials and potential commercial preparations well beyond the next 12 months.
Pipeline Milestones
Edgewise’s lead skeletal muscle candidate sevasemten is being evaluated in the Phase 2/3 GRAND CANYON study for patients with Becker muscular dystrophy. The company confirmed that the cohort remains on track for data readout in the fourth quarter of 2026. Concurrently, the MESA open-label extension study has enrolled nearly all eligible participants, providing long-term exposure data that could support eventual regulatory submissions.
In the cardiac franchise, the Phase 2 CIRRUS-HCM trial assessing EDG-7500 in hypertrophic cardiomyopathy continued to recruit during the quarter. A program update is scheduled for release in the fourth quarter of 2025. Separately, first-in-human dosing of EDG-15400 for heart failure commenced, marking a key step in exploring the compound’s safety and pharmacokinetics.
Each asset targets diseases with limited therapeutic options. Becker muscular dystrophy is a progressive muscle-wasting disorder caused by mutations in the dystrophin gene, while hypertrophic cardiomyopathy involves abnormal thickening of the heart muscle that can lead to arrhythmias and sudden cardiac death. For broader context on these conditions, the National Institutes of Health provides detailed background information on their prevalence and current treatment approaches.
Financial Position
The company’s $563.3 million cash position offers what management describes as a “runway” sufficient to complete current clinical studies and prepare for potential commercial launches if trials succeed. No guidance was issued on future financing needs, but the existing reserves are projected to cover operations through at least late 2027, based on current spending levels.
While Edgewise has not yet reported revenue, its operational strategy centers on progressing candidates through critical mid-stage and late-stage trials, then either securing regulatory approvals independently or partnering with larger pharmaceutical firms. The clinical timeline set for 2025 and 2026 will provide multiple data catalysts, beginning with the planned CIRRUS-HCM update next quarter.
Outlook
In the near term, investors will focus on enrollment metrics, safety observations, and interim efficacy signals from ongoing studies. Key upcoming events include:
- Fourth-quarter 2025 update on EDG-7500 in hypertrophic cardiomyopathy;
- Continued enrollment and safety monitoring in the MESA open-label extension for Becker muscular dystrophy;
- Progress reports on initial dosing cohorts for EDG-15400.
Edgewise noted no delays or protocol modifications for its trials during the period. Supply chain logistics, manufacturing capacity, and site activation timelines remained on schedule. The company did not disclose any partnership discussions or licensing agreements in its quarterly communication.
As clinical work accelerates, management expects R&D expenditures to remain the largest component of operating costs. Future expense variations will depend on patient recruitment rates, trial expansions, and chemistry-manufacturing-controls (CMC) activities required for potential marketing applications.
Crédito da imagem: Edgewise Therapeutics Investor Materials
